Our enzyme inhibition assessment service employs a range of in vitro techniques to evaluate the inhibitory potential of drugs on key enzymes involved in drug metabolism, such as CYP450 and UGT enzymes.
Learn More →Drug-Drug Interaction Analysis Services
Creative Biolabs' drug-drug interaction analysis services provide an integrated solution spanning enzyme and transporter in vitro screening through to quantitative PBPK modeling. We provide definitive mechanistic data, including transporter profiles and predicted R-value reports, essential for de-risking your compound. Our key advantage lies in combining this experimental rigor with knowledge graph-based predictive analytics for superior, early-stage identification of novel DDI liabilities, supported by the strategic guidance of expert pharmacologists.
Introduction What We Can Offer How We Can Help Why Creative Biolabs Customer Reviews FAQs Related Services Contact Us
Mechanism of Drug-Drug Interaction
When two or more drugs are administered simultaneously, they may interact with each other, impacting the efficacy and safety of the medications. Drug metabolism plays a crucial role in drug-drug interactions, as it can greatly influence drug concentrations in the body, subsequently affecting their therapeutic effects and potential side effects. A significant focus of research in drug-drug interactions is on the induction or inhibition of enzymes and transcription factors responsible for drug metabolism. For example, if a drug inhibits the metabolism of another drug, the concentrations of the second drug may increase, potentially leading to increased therapeutic effects or side effects. Conversely, if a drug induces the metabolism of another drug, the concentrations of the second drug may decrease, potentially reducing its therapeutic effectiveness. Through understanding these interactions, researchers can develop improved drug combinations and dosing regimens that enhance therapeutic outcomes while reducing potential risks.
Discover how we can help - Request a consultation.
Fig.1 A workflow of predicting DDI by fusing biochemical and structural information. 1, 3
What We Can Offer
Creative Biolabs, a leading provider of biotechnology services, offers a comprehensive range of services to help researchers understand and predict drug-drug interactions. Our services cover enzyme inhibition and induction assessment, reaction phenotyping assessment, reactive metabolite screening, and transporter interaction assessment. These services are designed to help researchers identify potential interactions between drugs and enzymes/transporters, assess reaction phenotypes, and profile metabolites. Our expertise and state-of-the-art facilities ensure accurate and reliable results, supporting your drug discovery and development efforts.
Enzyme Inhibition Assessment Service
Reaction Phenotyping Assessment Service
This service aims to accurately identify the specific enzyme phenotype involved in the in vitro metabolism of drugs. This involves incubating compounds with relevant biological matrices to determine the relative contributions of various isozymes.
Learn More →Enzyme Induction Assessment Service
Our service utilizes in vitro systems to assess the ability of test drugs to induce specific drug-metabolizing enzymes, such as cytochrome P450 enzymes. This information is crucial in predicting drug-drug interactions.
Learn More →Reactive Metabolite Screening Service
Creative Biolabs also provides comprehensive metabolite profiling and analysis of metabolites produced during drug exposure. By analyzing these key metabolites, we offer a deeper understanding of drug metabolism and predict potential DDI liabilities.
Learn More →Transporter Interaction Assessment Service
We provide validated in vitro models, including Caco-2 and transfected HEK-293 cells, to assess the inhibition potential towards a wide range of transporters, such as P-glycoprotein, BCRP, OATP1B1, and OATP1B3.
Learn More →Our Drug-Drug Interaction Analysis Service
Highlights
Customized Study Design
Creative Biolabs provides full scientific flexibility, tailoring DDI study protocols and sophisticated PBPK model development precisely to your therapeutic candidate's unique mechanism and current development stage.
Integrated PK/PD Workflow
Seamless execution of gold-standard in vitro screening (CYPs, UGTs, major Transporters) integrated directly with PBPK modeling for accurate, quantitative assessment of DDI risk magnitude.
Cutting-Edge Predictive Analytics
Utilization of our advanced frameworks, including Knowledge Graph methods, to proactively identify and characterize novel, non-obvious DDI liabilities early in the drug discovery phase.
Comprehensive Transporter and Enzyme Coverage
Full scope assessment of all critical metabolic pathways and transporters (e.g., P-gp, OATP, BSEP), ensuring maximum scientific confidence and minimal safety risk down the pipeline.
Discover how a partnership with us can streamline your research - Get a quote today.
Customer Reviews
-
Transporter Depth
Using Creative Biolabs' DDI analysis services in our research has significantly improved our understanding of tissue-specific DDI risk. Their ability to assess the full panel of efflux and uptake transporters, including BSEP, provided the essential data needed to de-risk our compound from potential DILI. - Dr. S***n Miller. -
Novel DDI Prediction
Using Creative Biolabs' DDI analysis services in our research has significantly improved early identification of non-obvious drug liabilities. The predictive analytics flagged a high-probability DDI with a co-medication outside our initial risk matrix. This insight changed our lead optimization strategy. - Dr. M***a Rodriguez.
FAQs
Q: How do you identify potential DDI risks that haven't been previously reported in the literature?
A: We use proprietary predictive analytics, which combines computational methods with comprehensive biological data. This approach identifies potential interactions by mapping underlying shared biological pathways and chemical properties.
Q: Is your DDI analysis compliant with the latest scientific best practices?
A: Absolutely. Our methodology aligns strictly with current best practices in pharmacokinetics and drug metabolism. Our comprehensive reports provide robust scientific justification for all DDI and RIS assessments performed.
Related Services
Drug Metabolic Stability Analysis Service
Essential determination of the intrinsic clearance and half-life of your compound using high-quality in vitro systems like microsomes and hepatocytes. This fundamental ADME data is crucial for predicting in vivo exposure.
Learn More →Drug Distribution Analysis Service
High-accuracy measurement of plasma protein binding and blood-to-plasma concentration ratio, fundamental data points required for calculating the unbound concentration that drives DDI risk assessment.
Learn More →How to Contact Us
Creative Biolabs' DDI analysis services offer an unparalleled combination of gold-standard in vitro precision and next-generation computational predictive modeling. We provide the definitive mechanistic insight required to de-risk your pipeline, satisfy demanding scientific criteria, and define safe, effective dosing strategies for your therapeutic candidate. Contact us now for more information and to discuss your project.
References
- Ren, Zhong-Hao et al. "BioChemDDI: Predicting Drug-Drug Interactions by Fusing Biochemical and Structural Information through a Self-Attention Mechanism." Biology vol. 11,5 758. 16 May. 2022. https://doi.org/10.3390/biology11050758
- Kamdar, Maulik R, and Mark A Musen. "PhLeGrA: Graph Analytics in Pharmacology over the Web of Life Sciences Linked Open Data." Proceedings of the ... International World-Wide Web Conference. International WWW Conference vol. 2017 (2017): 321-329. https://doi.org/10.1145/3038912.3052692
- Distributed under an Open Access license CC BY 4.0, without modification.
Download our brochureLoading case studies...
Online Inquiry